Healthcare and Life Science
Nxera Pharma receives approval of QUVIVIQ (daridorexant) in Japan for the treatment of insomnia
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary endpoints Plans to make QUVIVIQ available as soon as possible to insomnia patients in Ja...
Have a heart – learn CPR, says MP
In advance of World Heart Day, Daniel Zeichner, Member of Parliament for Cambridge, tried out RevivR, a new CPR training tool, at a British Heart Foundation (BHF) shop in Cambridge on Friday 20 September to highlight the charity's vital work in combating heart and circulatory diseases. ...
Hospital prosthetics service moves to high-tech new home
An Addenbrooke’s service that offers vital support for amputees and others officially opened on the 23rd Sept at a high-tech new home after nearly quarter of a century at the hospital. ...
impulse’s next-gen female entrepreneurs eye up $1trillion FemTech sector
With the FemTech market set to be worth $1trillion by 2027 (McKinsey & Company), impulse, the University of Cambridge’s unique entrepreneurship programme, has seen a sharp rise in the number of participants contributing novel innovations to this exciting sector. ...
Introducing Gluetacs Therapeutics to the UK market
Gluetacs Therapeutics (www.gluetacs.com), a pioneering biotech company located in the innovative Lin-gang Special Area of China (Shanghai) Pilot Free Trade Zone, is making significant strides in the field of targeted protein degradation, both in molecular glue (GLUE) and bifunctional ...
Milton Keynes University Hospital purchases second Versius system to bring robotic MAS to more patients
CMR Surgical (CMR) – the global surgical robotics business – has today announced that Milton Keynes University Hospital NHS Foundation Trust (MKUH) have installed their second Versius Surgical Robotic System. ...
ARU collaborates on new childhood cancer project
Scientists will work with Medannex to help accelerate treatment for bone cancer.
Nxera Pharma appoints experienced commercial R&D executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan
Tokyo, Japan and Cambridge, UK – Nxera Pharma Co., Ltd. – formerly known as Sosei Group or Sosei Heptares – announces the appointment of Dr. Makoto Sugita, M.D., Ph.D., MBA, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief M...
Maximizing the impact of chronic condition data collection
In the realm of healthcare, chronic conditions pose significant challenges for patients, caregivers, and healthcare providers alike. Effective management of chronic conditions requires a nuanced understanding of disease progression, treatment responses, and patient experiences. Data c...
Key challenges in the medical device startup landscape
Co-authored by Samantha Shelley, SQMS.